β3Gn-T1 Inhibitors

β3Gn-T1 inhibitors largely target the general process of glycosylation, a crucial post-translational modification. Among the primary inhibitors is tunicamycin, which impedes the early steps of glycosylation in the endoplasmic reticulum by targeting N-acetylglucosamine transferase. Given that β3Gn-T1 is also a N-acetylglucosaminyltransferase, this compound can provide a significant disruptive effect on its function. Swainsonine and deoxymannojirimycin inhibit mannosidase, impacting the processing of N-linked glycoproteins, which again can indirectly hinder β3Gn-T1's operations.

Compounds like 2-Deoxy-D-glucose provide a broad disruption to glycosylation by imitating glucose and competing with it, affecting any enzyme in the pathway that relies on glucose, including β3Gn-T1. Similarly, glucosidase inhibitors like castanospermine and NB-DNJ alter the processing and maturation of glycoproteins within the endoplasmic reticulum, creating an environment where β3Gn-T1's functionality might be compromised. Additionally, glycosylation's close ties with glycolipid synthesis introduce compounds like miglustat, which targets glucosylceramide synthase. Disruptions in these pathways can lead to broader disturbances in cellular glycosylation processes, indirectly impacting β3Gn-T1.